Management of IBD patients during the COVID-19 pandemic

Stephen B. Hanauer; Gary R. Lichtenstein

Management of IBD patients during the COVID-19 pandemic

Stephen B. Hanauer, Gary R. Lichtenstein^*

^*Corresponding author for this work

Medicine, Gastroenterology Division

Research output: Contribution to journal › Comment/debate › peer-review

Original language	English (US)
Pages (from-to)	577-580
Number of pages	4
Journal	Gastroenterology and Hepatology
Volume	16
Issue number	11
State	Published - Nov 2020

Funding

Dr Lichtenstein has consulted for AbbVie, American Regent, Celgene, CellCeutix, Eli Lilly, Endo Pharmaceuticals, Ferring, Gilead, Janssen Orthobiotech, Merck, Morphic Therapeutics, Pfizer Pharmaceuticals, Prometheus Laboratories, Romark, Salix Pharmaceuticals/Valeant, Shire Pharmaceuticals, Takeda, and UCB; conducted research for Celgene, Janssen Orthobiotech, and UCB; served on the DSMB for Eli Lilly; received honorarium (CME program) from American Regent, Merck, and Romark; and received funding to the University of Pennsylvania (IBD fellow education) from Janssen Orthobiotech, Pfizer Pharmaceuticals, and Takeda.

ASJC Scopus subject areas

Hepatology
Gastroenterology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

@article{3817b3cdd8904fcc906e780ec2d9db37,

title = "Management of IBD patients during the COVID-19 pandemic",

author = "Hanauer, {Stephen B.} and Lichtenstein, {Gary R.}",

note = "Funding Information: Dr Lichtenstein has consulted for AbbVie, American Regent, Celgene, CellCeutix, Eli Lilly, Endo Pharmaceuticals, Ferring, Gilead, Janssen Orthobiotech, Merck, Morphic Therapeutics, Pfizer Pharmaceuticals, Prometheus Laboratories, Romark, Salix Pharmaceuticals/Valeant, Shire Pharmaceuticals, Takeda, and UCB; conducted research for Celgene, Janssen Orthobiotech, and UCB; served on the DSMB for Eli Lilly; received honorarium (CME program) from American Regent, Merck, and Romark; and received funding to the University of Pennsylvania (IBD fellow education) from Janssen Orthobiotech, Pfizer Pharmaceuticals, and Takeda.",

year = "2020",

month = nov,

language = "English (US)",

volume = "16",

pages = "577--580",

journal = "Gastroenterology and Hepatology",

issn = "1554-7914",

publisher = "Gastro-Hep Communications, Inc.",

number = "11",

}

TY - JOUR

T1 - Management of IBD patients during the COVID-19 pandemic

AU - Hanauer, Stephen B.

AU - Lichtenstein, Gary R.

N1 - Funding Information: Dr Lichtenstein has consulted for AbbVie, American Regent, Celgene, CellCeutix, Eli Lilly, Endo Pharmaceuticals, Ferring, Gilead, Janssen Orthobiotech, Merck, Morphic Therapeutics, Pfizer Pharmaceuticals, Prometheus Laboratories, Romark, Salix Pharmaceuticals/Valeant, Shire Pharmaceuticals, Takeda, and UCB; conducted research for Celgene, Janssen Orthobiotech, and UCB; served on the DSMB for Eli Lilly; received honorarium (CME program) from American Regent, Merck, and Romark; and received funding to the University of Pennsylvania (IBD fellow education) from Janssen Orthobiotech, Pfizer Pharmaceuticals, and Takeda.

PY - 2020/11

Y1 - 2020/11

UR - http://www.scopus.com/inward/record.url?scp=85098556613&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85098556613&partnerID=8YFLogxK

M3 - Comment/debate

AN - SCOPUS:85098556613

SN - 1554-7914

VL - 16

SP - 577

EP - 580

JO - Gastroenterology and Hepatology

JF - Gastroenterology and Hepatology

IS - 11

ER -

Management of IBD patients during the COVID-19 pandemic

Funding

ASJC Scopus subject areas

UN SDGs

Other files and links

Cite this